Category: Biophytis
-
H.C. Wainwright optimistic on Biophytis stock as Phase 2 trial approved By Investing.com
•
HC Wainwright on Friday affirmed its buy rating and $15.00 price target on Biophytis SA (NASDAQ:BPTS) stock, following the company’s announcement that it has received FDA approval to begin a Phase 2 clinical study. The study, which will focus on BIO101 in patients with obesity, is scheduled to begin in…